Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women
Journal of Obstetrics and Gynaecology Research · 2026
DOI: 10.1111/jog.70309 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Kunio Kitamura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Japan Family Planning Association, Tokyo, Japan. Hauptthemen laut MEDLINE: Androstenes. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ASKA Pharmaceutical Co. Ltd.
Abstract (Originalsprache)
Aim
We conducted a 24‐cycle study to evaluate long‐term safety of 4 mg of drospirenone (DRSP), a progestin‐only pill (POP), for contraception in Japanese women.
Methods
A multicenter, single‐arm 24‐cycle study was conducted in women who participated in the 13 cycle study of DRSP. In each cycle, 4 mg of DRSP tablet was administered orally once daily for 24 consecutive days, followed by a placebo tablet for 4 days.
Results
In this 24‐cycle study, the total number of DRSP exposure cycles was 3878. Fifty‐two subjects (100.0%) experienced treatment‐emergent adverse events (TEAEs), and 50 (96.2%) experienced adverse drug reactions. All TEAEs were mild or moderate with no severe events. The most common TEAE was intermenstrual bleeding, which occurred in 49 (94.2%) subjects. Although 50.0% of the subjects had risk factors for venous thromboembolism (VTE), no VTE‐related TEAEs were observed. No TEAEs led to discontinuation of the study. During 3878 exposure cycles, pregnancy occurred in one subject. The overall Pearl index [95% CI] was 0.34 [0.01, 1.87], and the cumulative pregnancy rate was 0.4%.
Conclusions
In this study, the safety of DRSP, the first POP in Japan, was evaluated in Japanese women for 24 cycles. The DRSP‐only pill provides a new option for contraception for Japanese women, including those at risk of developing VTE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Family Planning Association, Tokyo, Japan.
- Exeltis, Madrid, Spain.
- ASKA Pharmaceutical Co., Ltd, Tokyo, Japan.
Förderung
- ASKA Pharmaceutical Co. Ltd
Zitieren
APA
Kitamura, K., Colli, E., Kikuyama, R., Kurihara, Y., Azuma, R., & Kagawa, T. (2026). Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70309
Vancouver
Kitamura K, Colli E, Kikuyama R, Kurihara Y, Azuma R, Kagawa T. Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70309
BibTeX
@article{Kitamura2026,
author = {Kitamura, Kunio and Colli, Enrico and Kikuyama, Ryoko and Kurihara, Yumiko and Azuma, Rieko and Kagawa, Tomoya},
title = {Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2026},
doi = {10.1111/jog.70309}
}
EUVIMED